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associated with calci¿ cation and extracellular lipid deposits in the ¿ brosa and 
the subendothelial layer of the aortic side of the leaÀ ets. Furthermore, their 
expression was signi¿ cantly higher in calci¿ ed regions of the leaÀ ets. We 
showed for the ¿ rst time the presence of TFPI-2 in aortic valves. Interestingly, 
TFPI-2 protein expression was found to be signi¿ cantly lower in the calci¿ ed 
regions (p=0.001). The same results were found for TFPI-2 mRNA expression.
Conclusion: We showed here for the ¿ rst time, the presence of TFPI-2 in 
calci¿ ed human aortic valves. The higher expression of TFPI-2 in the less 
calci¿ ed regions of the valves might suppose a protective role for TFPI-2 in 
aortic valve disease.
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Context: Limited data exist regarding epidemiological changes in infective 
endocarditis (IE) incidence and characteristics due to medical progress and 
to the as-recommended decrease in IE antibiotic prophylaxis in patients with 
native-valve disease undergoing dental procedures.
Objective: To evaluate temporal trends in age- and sex-standardized IE 
annual incidence and clinical characteristics, in the overall population and 
according to underlying heart disease and causative microorganisms.
Methods: Three one-year population-based surveys in 1991, 1999 and 
2008, in all medical centers from three French regions totaling 11 million 
inhabitants 20 years and older.
Results: 993 patients were included. IE incidence remained stable over 
time: 35 (95% con¿ dence interval, [31-39]), 33 [30-37] and 32 [28-35] cases 
per million in 1991, 1999 and 2008, respectively, with no oral streptococci 
IE incidence increase since the 2002 French IE prophylaxis guideline modi-
¿ cations (8.1 [6.4-10.1], 6.3 [4.8-8.1], 6.3 [4.9-8.0]). The Staphylococcus 
aureus IE incidence increase (5.2 [3.9-6.8], 6.8 [5.3-8.6], 8.2 [6.6-10.2]) was 
not signi¿ cant in the global population but was signi¿ cant in patients without 
previously known native valve disease (1.6 [0.9-2.7], 3.7 [2.6-5.1], 4.1 [3.0-
5.6]; p=0.012). Mean age and proportions of patients with diabetes mellitus 
and cerebral emboli rates increased signi¿ cantly over time whereas proportion 
of previously known underlying heart disease markedly decreased. In-hospital 
mortality remained high (20.7%, 15.4%, 21.2%) and was independently asso-
ciated with age and staphylococcal IE in all three surveys.
Conclusion: IE characteristics continue to change rapidly. To date, the res-
trictions of antibiotic prophylaxis indications are not associated with increased 
incidence of oral streptococcal IE. High in-hospital mortality was associated 
with characteristics (older age, staphylococci) of increasing prevalence.
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Myxomatous Valvular Dystrophy (MVD) is a frequent valvular disease cha-
racterized by the thickening and lengthening of valve leaÀ ets causing regurgi-
tation. We previously identi¿ ed Filamin A (FlnA) as the ¿ rst gene linked to 
nonsyndromic MVD but the physiopathological mechanisms remain to be eluci-
dated. The purpose of this study is to identify the molecular and cellular mecha-
nisms involved in MVD associated to FlnA mutations P637Q and G288R.
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Background: Chordal rupture (CR) has been scarcely reported as a cause 
of severe mitral regurgitation (MR) in hypertrophic cardiomyopathy (HCM) 
and its mechanisms remain unclear.
Material and Methods: This retrospective monocentric study was 
conducted using hospital computer ¿ les between 2000-2010.
Results: Among 580 patients hospitalized for HCM, 6 (1%; 5 males; age: 71 
[68-77] years) presented with echocardiographic (echo) CR revealed by heart 
failure. Pre-rupture echo showed leaÀ et elongation (anterior leaÀ et: 29 mm; poste-
rior leaÀ et [PL]: 17 mm) and resting left ventricular outÀ ow obstruction (LVOT) 
in 5 cases (55 [44-70] mmHg) due to systolic anterior motion (SAM) with normal 
ejection fraction and mild to moderate MR without mitral valve prolapse (MVP). 
Post-rupture echo showed that CR constantly involved the PL, leading to severe 
MR, while SAM/LVOT disappeared in 3 patients and increased the others (49 to 
76 mmHg [20-100%]). MRI found ¿ brosis of the posterior papillary muscle in a 
single case. Surgery was performed in 5 cases with successful repair in 3 cases. 
Histology showed constant, diffuse and severe myxomatous degeneration.
Conclusion: CR, always involving the PL, is uncommon in HCM and 
might be due to valve elongation, myocardial ¿ brosis and myxomatous dege-
neration. The later was inconstantly reported and was thought to be due to the 
association HCM/MVP, which was not observed here, suggesting a degenera-
tion process secondary to valvular stress in HCM.  
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Background: Human tissue factor pathway inhibitor-2 (TFPI-2) is known 
to have inhibitory activity toward matrix metalloproteases (MMPs) which are 
known to play an important role in the initiation and progression of aortic 
valve stenosis (AS). The reduced synthesis of TFPI-2 has been related to 
numerous pathophysiological processes such as atherosclerosis. Since AS is an 
atherosclerotic-like process, we hypothesized that TFPI-2 might play a protec-
tive role in the progression of AS and therefore evaluated the valvular expres-
sion and localization of TFPI-2.
Methods: Calci¿ ed aortic valves (n=34) were obtained from patients 
undergoing aortic valve replacement (21 men; age 69±2 years, mean aortic 
valve area 0.80±0.04cm²). LeaÀ et structure, cellular and lipid in¿ ltration and 
expression of TFPI-2 and other components of atherosclerosis were evaluated 
immunohistochemical staining. TFPI-2, Tissue factor (TF), osteopontin and 
MMP expressions were measured using ELISA. Finally, we performed semi-
quanti¿ cation of TFPI-2 transcripts by RT- PCR and further analyzed protein 
expression by Western blot.
Results: We con¿ rmed our earlier results, that the expression of pro-athe-
rosclerotic factors (TF, MMPs) and pro-calcifying protein (osteopontin) were 
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Methods: Two-hundred eight patients (62±13 years, 135 males) with 
moderate to severe organic MR underwent an echocardiographic examination 
and left and right ventricular assessment by radionuclide angiography. The 
left ventricle (LV) was divided into 9 regions to assess regional LV function.
Results: Mean RV EF was 40±10%, ranging from 10 to 65%. One hundred 
¿ fty-one patients were in sinus rhythm, and 57 patients (27%) in atrial ¿ brilla-
tion. Tricuspid annulus S wave velocity measured in a subset of patients 
(n=92) correlated weakly with RV EF (r=0.27, P=0.018). Fifty-nine patients 
(28%) had a RV EF 35%. Patients with RV EF 35% had lower systolic 
blood pressure (P=0.045), larger RV (P=0.007), higher pulmonary artery sys-
tolic pressure (PASP, P=0.045) and had more diuretics (P=0.009) compared 
with those with RV EF >35%. In univariate analysis, echocardiographic pre-
dictors of RVEF were LVEF (r=0.33, P<0.0001), LV end-diastolic diameter 
(r=-0.26, P=0.001) and volume (r=-0.29, P=0.001), left atrial size (r=-0.22, 
P=0.003), mitral E velocity (r=-0.29, p<0.0001), PASP (r=-0.22, p=0.004), and 
aortic stroke volume (r=0.31, p=0.007). In the subset of patients with effective 
regurgitant ori¿ ce (ERO) and regurgitant volume quanti¿ cation RV EF corre-
lated with ERO (r=-0.34, P=0.005) and regurgitant volume (r=-0.33, P=0.008). 
RV EF correlated closely with radionuclide LV septal function (regional LV 
EF 8: r=0.49, P<0.0001). In multivariate analysis, LV septal function (r=0.43, 
P<0.0001) was the main determinant of RV function. LV end-diastolic dia-
meter (r=-0.25, P<0.0001) and PASP (r=-0.18, P=0.009) were also indepen-
dent predictors of RVEF.
Conclusion: In organic mitral regurgitation RV function depends not only 
on PASP but also on LV remodeling and function. 
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Background: There is currently uncertainty and debate regarding whether 
ischemic mitral regurgitation (MR) is a secondary epiphenomenon resulting 
from LV dysfunction or confers an independent effect on exercise capacity and 
outcomes; this debate impacts management.
Objective: We tested whether ischemic MR negatively impacts exercise 
capacity, cardiovascular morbidity and mortality in patients (pts) with coro-
nary artery disease (CAD) independent of LV dysfunction.
Methods: Clinical follow-up over 5 years was obtained in 77 consecu-
tive pts (age 64±10 years, LVEF 54±11%) with stable CAD who had exercise 
stress testing with perfusion imaging within 24 hours of echocardiography. Pts 
with active heart failure, ischemia, intrinsic valve disease, pulmonary and vas-
cular disease were excluded. Exercise capacity (METs, peak double product) 
was tested for relation to MR (vena contracta (VC) and jet area), LV size 
and function, and pulmonary pressures. Cox proportional hazards analysis 
assessed whether MR predicted cardiovascular events, including hospitaliza-
tion for heart failure, acute coronary syndrome, and myocardial infarction, and 
cardiovascular (CV) and total mortality.
Results: By multivariate analysis, independent predictors of functional 
capacity (METs and peak double product) were MR vena contracta (VC; 
r²=0.62, p<0.0001) and LV end-diastolic volume (EDV; r²=0.78, p=0.03). MR 
jet area contributed similarly (r²=0.61, p<0.0001). MR VC > 2 mm (mode-
rate ischemic MR) and age were the independent predictors of CV events and 
death (HR 6.72 for MR, p=0.04).
Conclusion: In patients with CAD, MR reduces exercise capacity and is 
associated with increased cardiovascular morbidity and mortality, independent 
of LV dysfunction, suggesting an adverse effect of MR volume load per se on 
functional capacity and outcomes.
Determinants of functional capacity (METS)
Stables cell lines expressing wild type (WT), FlnA-P637Q or G288R 
mutants were established in the FlnA-de¿ cient human melanoma cell line 
(M2). Previous studies showed that in these cells, FlnA de¿ ciency was asso-
ciated with cellular cortical actin network disorganisation which determined 
blebs formation on M2 cells surface. Here, we showed that like WT-FlnA, 
mutant FlnA suppressed blebs formation indicating “normal” actin network 
was rebuilt. On the other hand, cells expressing mutant FlnAs were smaller 
and exhibited reduced cellular extension (lamellipodia and ¿ lopodia). Mutant 
FlnA expressing cells also exhibited reduced cell migration, adhesion and 
extracellular matrix (¿ bronectin) organization capabilities. Interestingly, these 
phenotypical features were associated with reduced E1 integrin expression. We 
showed that whereas QPCR experiments revealed similar transcription levels 
of E1 integrin mRNA in WT and mutant-FlnA expressing cells, the latter exhi-
bited increased E1 Integrin protein degradation.
In conclusion, our experiments show that FlnA mutations associated with 
MVD affect E1 Integrin expression. The peculiar involvement of E1 integrins 
at the crossroad of mechanical stress, cytokines (TGFE), extracellular matrix 
remodelling signalling pathways should enable us to make great inroads in our 
understanding of FlnA associated MVD physiopathology.
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Recent safety data emphasized that chronic 5-HT2B valvular receptor sti-
mulation can induce cardiac valve degeneration. In carcinoid heart which is 
the main complication of carcinoid tumours, patients exhibit clinical signs of 
right heart failure due to the combination of tricuspid valve insuf¿ ciency and 
pulmonary valve stenosis. Serotonin (5-HT), the main vasoactive substance 
produced by the tumour, has been suggested as a major contributor to heart 
lesions but, no clear proof has been provided to this assumption. We postulated 
that liver metastasis from the primary gut tumour secrete and release 5-HT to 
the right heart. 5-HT could then stimulate valvular cells expressing 5-HT2B 
receptors to induce carcinoid plaque deposition leading to valvulopathy. We 
developed a new experimental model by combining endothelial dysfunction 
(induced by L-NAME) to intrasplenic xenograft of BON human carcinoid cell 
line in Swiss CD1 nude male mice. In this approach, we characterized BON 
carcinoid cells by demonstrating that they contain 5-HT (>1000g/L/105 cells) 
and secrete 5-HT in their culture medium (>25g/L/105 cells). Moreover, we 
demonstrated by Western blots and RT-PCRs their expression of serotonergic 
and carcinoid cells markers (TPH1, SSTR2, 5-HT2BR, SERT). In these cells, 
the selective 5-HT2B receptors blockade by SB206553 signi¿ cantly reduced 
cells proliferation rate (-20% vs control). Swiss CD1 xenografted nude mice 
exhibited liver metastasis and high amounts of blood serotonin ( >3500g/L 
vs 2100 g/L in controls) 90 days after cells injection. Histopathological ana-
lysis of tricuspid valves showed typical features of carcinoid plaques. In this 
model, we showed that the inhibition of 5-HT synthesis and 5-HT2B recep-
tors blockade by ritanserin affected the rate of liver metastasis and prevented 
cardiac lesions. This model is now used to deeply investigate the contribution 
of 5-HT in cardiac remodelling and the pharmacological mechanisms that lead 
to valvulopathy.
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Objectives: The aim of this study was to assess right ventricular (RV) ejec-
tion fraction (EF) and its determinants in patients with organic mitral regurgi-
tation (MR) by radionuclide angiography.
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